G. N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia.
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
Bull Exp Biol Med. 2021 Mar;170(5):636-639. doi: 10.1007/s10517-021-05122-6. Epub 2021 Mar 31.
The bactericidal activity of recombinant endolysins LysECD7, LysAm24, LysAp22, LysSi3 and LysSt11 was assayed in multidrug resistant strains (n=120) of Salmonella enterica, E. coli, Acinetobacter baumannii, Enterobacter spp., Pseudomonas aeruginosa, Klebsiella pneumoniae, and Campylobacter jejuni. The assay showed that the recombinant endolysins had a wide spectrum of bactericidal activity compared to endolysins of their progenitor phages. Among examined endolysins, we selected the active pharmaceutical substances with broad spectrum of bactericidal activity. Most strains were sensitive to LysECD7 (70.7%), LysAm24 (65%), and LysAp22 (58.6%), which seems to be promising causative agents for the development of finished dosage form.
研究人员测定了重组溶菌酶 LysECD7、LysAm24、LysAp22、LysSi3 和 LysSt11 对 120 株耐多药鼠伤寒沙门氏菌、大肠杆菌、鲍曼不动杆菌、肠杆菌属、铜绿假单胞菌、肺炎克雷伯菌和空肠弯曲菌的杀菌活性。结果表明，与亲代噬菌体的溶菌酶相比，重组溶菌酶具有广谱杀菌活性。在检测到的溶菌酶中，我们选择了具有广谱杀菌活性的活性药物物质。大多数菌株对 LysECD7（70.7%）、LysAm24（65%）和 LysAp22（58.6%）敏感，这似乎是开发成品剂型的有前途的病原体。
